Doximity's potential as a stock to explode in the next 3 years

What happened: Doximity, Inc. (DOCS), a digital platform for U.S. medical professionals, has gained bullish attention from investors. As of April 21st, DOCS traded at $24.15, with trailing and forward P/E ratios of 20.29 and 15.29 respectively. The Cash Flow Compounder's Substack highlighted DOCS as a potential stock to buy, while ClearBridge Investments' first-quarter 2026 commentary noted DOCS' share weakness due to AI disruption concerns.

Market impact: The healthcare IT sector is affected, with DOCS' platform strength and growth prospects driving investor sentiment. The stock's recent weakness, fueled by AI disruption fears, has led to a mix of bullish and bearish views, reflecting the broader market's uncertainty about the impact of AI on established businesses.

What to watch next: Upcoming catalysts include DOCS' Q2 2026 earnings release (scheduled for May 10th), which will provide insights into the company's growth and AI-related headwinds. Additionally, further clarity on regulatory support for telehealth services and AI integration in healthcare could influence DOCS' stock performance.